Cheng Han Biotech Announces Board Resolution to Issue First Domestic Secured Convertible Corporate Bonds

1. Date of Board Resolution: 115/08/19 2. Name (XX Company's Xth Secured/Unsecured Corporate Bond): First Domestic Secured Convertible Corporate Bond of Cheng Han Biotech Co., Ltd. 3. Whether the issuance of corporate bonds is declared under a general application (Yes/No): No 4. Total Issuance Amount: NT$700 million 5. Face Value per Unit: NT$100,000 6. Issue Price: Issued at 100% to 101% of face value 7. Term: 3 years 8. Interest Rate: Coupon rate of 0% 9. Type, Name, Amount, and Terms of Collateral: Bank Guarantee 10. Use of Proceeds and Funding Plan: Repayment of bank loans and enhancement of operating funds 11. Underwriting Method: Public offering via book-building 12. Bond Trustee: Taipei Fubon Commercial Bank Co., Ltd. 13. Underwriter or Distributor: Fubon Financial Holding Securities Co., Ltd. 14. Issuance Guarantor: O-Bank Co., Ltd. 15. Agency for Principal and Interest Payment: Shareholder Services Division, Mega Securities Co., Ltd. 16. Certification Agency: Not applicable due to dematerialized issuance 17. Conversion Terms for Eligible Shares: The relevant terms shall be established in accordance with applicable laws and regulations, submitted to the competent authority for approval, and separately announced thereafter. 18. Put Option Terms: The relevant terms shall be established in accordance with applicable laws and regulations, submitted to the competent authority for approval, and separately announced thereafter. 19. Call Option Terms: The relevant terms shall be established in accordance with applicable laws and regulations, submitted to the competent authority for approval, and separately announced thereafter. 20. Share Conversion Benchmark Date for Convertible, Exchangeable, or Subscription Rights-Attached Instruments: The relevant terms shall be established in accordance with applicable laws and regulations, submitted to the competent authority for approval, and separately announced thereafter. 21. Potential Dilution of Equity for Convertible, Exchangeable, or Subscription Rights-Attached Instruments: The relevant terms shall be established in accordance with applicable laws and regulations, submitted to the competent authority for approval, and separately announced thereafter. 22. Rationality and Necessity of Fundraising Following Cash Capital Reduction (Applicable if cash capital reduction was conducted in the current or previous year): Not applicable 23. Other Matters to be Disclosed: The issuance terms, actual raised amount, conversion price and method, project plans, expected progress, and other related matters of these corporate bonds may be revised due to regulatory amendments or changes in objective circumstances. The Chairman is hereby authorized to fully handle such revisions in accordance with relevant regulations.